Product
L19-IL2
1 clinical trial
1 indication
Indication
Diffuse Large B-cell LymphomaClinical trial
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status: Terminated, Estimated PCD: 2023-09-01